Plain English Summary
Background and study aims
Anorexia Nervosa (AN) is a serious disorder with often devastating consequences. Treatment outcomes are poor with only about 3 out of 10 in remission after one year of specialist treatment. Thus there is a strong need for new treatment strategies. From several studies evidence is emerging that self regulatory ability is weakened in a range of neuropsychiatric disorders, including AN. This could be a consequence of developmental dysfunction in fronto-striatal circuits (neural pathways in brain). High frequency repetitive transcranial stimulation (rTMS) improve self regulatory control and thus symptomatology in disorders that have a fronto-striatal dysfunction, such as bulimia nervosa or obsessive compulsive disorders. The specific aims of this two part study are firstly, to conduct as study to investigate the effects of one session of repetitive transcranial magnetic stimulation (rTMS) compared to sham rTMS in reducing negative emotions and preoccupation toward food and shape. This could increase food intake by increasing self regulatory control over compensatory behaviours such as restriction. This extends our recent findings of increased self-regulatory control as expressed by reduced craving and binge eating in people with a bulimic eating disorder. Secondly, a feasibility case series study will also be conducted in which a small number of individuals with AN will be offered 20 sessions (3 days per week) of rTMS over 6 weeks in order to establish whether a longer, therapeutic delivery of rTMS improves self-regulatory control over eating.
Who can participate?
In order to be eligible to take part in the study participants must be over the age of 18, right-handed and have a current diagnosis of Anorexia Nervosa or EDNOS-anorexia type (EDNOS: Eating Disorder Not Otherwise Specified).
What does the study involve?
Participation involves having a MRI brain scan and a real or sham (placebo) rTMS session. In order to detect the effects of rTMS not all participants will receive real rTMS, that is half of the participants will receive a sham (placebo) rTMS stimulation. This will be a random allocation and participants will not be aware of which (real or sham) stimulation they receive, however will be informed upon completion of the study. Participants will also be required to complete a number of questionnaires (assessing mood and eating habits), ratings in relation to different food types and a neuropsychological task (brain puzzle) immediately before and after the stimulation session. We will also collect saliva samples to measure cortisol (this is a stress hormone).
What are the possible benefits and risks of participating?
The most common side effect of rTMS is a mild discomfort in the scalp beneath the magnetic coil, but some people also referred to a mild headache (easily treated with simple analgesic drugs). The magnetic coil makes loud clicks during treatment that are not loud enough to harm hearing, but patients will be asked to wear earplugs as a precaution. The coil can be changed during the procedure because it may warm up. This would only be slightly above body temperature and would never cause skin or hair damage. An inbuilt safety mechanism in the machine makes it switch off automatically when it has reached 40 degrees Celsius. Although the rTMS is seen as a safe procedure, the most serious side effect reported, though very rare, is a seizure. Regarding cardiac safety of the procedure, we have observed this procedure to be safe in people with bulimic disorders. The rTMS Adult Safety Screen will be done before rTMS and a final evaluation of discomfort with the rTMS procedure will also be done with another VAS (none to extreme discomfort). In addition, a list of side effects that have been reported with rTMS as recommended by the Safety of TMS Consensus Group will be checked. There are no risks associated with the administration of the interviews, neuropsychological tests and other questionnaires or saliva collection. No specific benefit is expected besides a possible reduction in their self regulatory control over behavioural symptoms such as food restriction. Nonetheless, the latter is expected to be relatively brief in duration for individuals participating in the RCT (hours) however slightly longer for those participating in the case series (days/weeks).
Where is the study run from?
Participants will be recruited from the outpatients eating disorder service at the Maudsley hospital, and via advertisements on the b-eat (national eating disorder charity) website. The testing will be conducted at the Institute of Psychiatry, London.
When is the study starting and how long is it expected to run for?
We expect to recruit and test participants from February 2013 up until September 2014.
Who is funding the study?
Eating Disorders Unit, Institute of Psychiatry, King's College London (UK) - Departmental funds
Who is the main contact?
Ms Jessica McClelland
Ms Jessica McClelland
P059 Section of Eating Disorders
Department of Psychological Medicine
103 Denmark Hill
Institute of Psychiatry
De Crespigny Park
+44 (0)20 7848 0183
An integrated study of (a) an experimental sham controlled randomised trial (RCT) of one session of repetitive Transcranial Magnetic Stimulation (rTMS) and (b) a 20 session feasibility case series of therapeutic rTMS in outpatients with Anorexia Nervosa (AN)
rTMS in AN
Based on our previous pilot study and the ability of rTMS to stimulate underlying cortical areas, we hypothesise that; in people with AN who are presented with highly appetising food stimuli real, high-frequency neuronavigated rTMS applied to the left dorsolateral prefrontal cortex (DLPFC), compared to sham rTMS, will lead to a reduction in:
1. Wanting to restrict food intake
2. Perceived stress and negative emotions
3. Food, eating and body related preoccupations; and
4. Salivary cortisol levels
The intervention will also lead to an improvement in body/interoceptive awareness and neuropsyhological tasks. Lastly, it will lead to an increase in food intake.
NRES Committee London - City & East, 02/11/2012, ref: 12/LO/1525
Randomised parallel-group double-blind study
Primary study design
Secondary study design
Randomised parallel trial
Patient information sheet
Not available in web format, please use the contact details below to request a patient information sheet
In the RCT, 64 participants will be randomised to receive real or sham rTMS in a parallel group double blind design. Ten participants from the RCT will do the feasibility study of 20 sessions of real rTMS 3 x week.
Repetitive Transcranial Magnetic Stimulation (rTMS) consists of a coil that is held by the researcher over the head of the participant which delivers pulses of magnetic field with a preselected frequency (10Hz in this study) and strength (determined individually as 110% of the motor threshhold). An individuals motor threshold will be determined by finding the minimum stimulus output to evoke 5 out of 10 motor evoked potentials greater than 50 microvolts. The target site for stimulation, the left DLPFC will be located using the brain scans acquired earlier in the day from the structural MRI. Neuronavigation software called Brainsight will be used to locate the area from the scan uploaded. After defining the exact area for stimulation, participants will be given 20 trains of 5 seconds (1000 pulses) with rest intervals of 55 seconds. This protocol is similar to those used in other studies and are within those recommended for safe use.
The sham rTMS makes the same noise but does not deliver any magnetic field. For the case series study, rTMS will be applied in 20 separate sessions, using the same parameters as the RCT.
Primary outcome measures
The specific aim of both the RCT and the case series is to investigate the effects of repetitive transcranial magnetic stimulation (rTMS) on preoccupation with food, eating, weight and shape in people with Anorexia Nervosa (AN). The primary outcome measures used to asses this are Visual Analogue Scale (VAS) measuring levels of stress, anxiety, urge restrict, urge exercise, feeling fullness and feeling fat. In addition, the Depression Anxiety Stress Scale (DASS) and Eating Disorders Examination Questionnaire (EDE-Q) will be primary outcome measures in the feasibility case series study.
Secondary outcome measures
The secondary aims of the RCT is to investigate the effects of rTMS on a) performance in neuropsychological tasks, b) stress levels as measured by cortisol (a stress hormone that can be measured in saliva). In addition, we will investigate the acceptability and tolerability of rTMS in people with AN. The secondary outcome measures used to asses these are a computerised delayed discounting task, salivettes which collect saliva samples when chewed and VAS which asses tolerance and acceptability of rTMS.
Overall trial start date
Overall trial end date
Participant inclusion criteria
1. Male and female participants who are aged 18 to 40
2. Body mass index (BMI) between 14 and 18.5 kg/m2
3. Current Diagnostic and Statistical Manual of Mental Disorders, 4th Edition (DSMIV) diagnosis of AN Restricting type (ANR), AN Binge/purging type (ANBP) or EDNOS anorexia type (EDNOSAN) (EDNOS: Eating Disorder Not Otherwise Specified)
Target number of participants
64 (RCT) and 10 (Feasibility Study)
Participant exclusion criteria
1. Having a history of head or eye injury
2. Having a history of a neurological disease including previous seizures of any kind
3. Having metallic implants in the head
4. Being dominantly left-handed
5. Being on a dose of any psychotropic medication that has not been stable for at least 14 days prior to participation in the study
6. Taking antipsychotic medication
7. Taking anticonvulsive medication
8. Being pregnant
9. Smoking more than 10 cigarettes /day
10. Having a current other major psychiatric disorder (e.g. major depressive disorder, substance dependence, schizophrenia or bipolar disorder) needing treatment in its own right
11. Severe abnormalities in their blood test during the month prior to the study
12. An rTMS safety questionnaire will also be administered and if considered not safe to deliver rTMS, people will subsequently be excluded on this basis
Recruitment start date
Recruitment end date
Countries of recruitment
Trial participating centre
Institute of Psychiatry
King's College London (UK)
c/o Jenny Liebscher
Institute of Psychiatry/South London and Maudsley NHS Foundation Trust
PO05 R&D Office
De Crespigny Park
+44 (0)20 7848 0251
King’s College London
Funding Body Type
Funding Body Subtype
Results and Publications
Publication and dissemination plan
Not provided at time of registration
Intention to publish date
Participant level data
Not provided at time of registration
Results - basic reporting
2016 results in: http://www.ncbi.nlm.nih.gov/pubmed/27008620